Skip to main content

Market Overview

Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer Settings

  • Molecular Templates Inc (NASDAQ: MTEM) has entered into a worldwide strategic research collaboration with Bristol-Myers Squibb Co (NYSE: BMY) to discover new molecules utilizing MTEM's engineered toxin body (ETB) platform for specific oncology targets.
  • Under the terms of the agreement, MTEM will conduct research activities to discover ETBs for multiple targets, of which Bristol Myers Squibb has selected the first target.
  • BMY will have the option to obtain an exclusive worldwide license to develop and commercialize ETBs directed to each selected target. Following the exercise of the option, Bristol Myers Squibb would be solely responsible for developing and commercializing the licensed ETBs.
  • MTEM will receive an upfront payment of $70 million from BMY and is eligible to receive milestone payments of up to approximately $1.3 billion and tiered royalty payments on future sales.
  • Price Action: MTEM increased 24.9% at $16 during premarket hours on the last check Thursday.

Related Articles (BMY + MTEM)

View Comments and Join the Discussion!

Posted-In: cancer oncologyBiotech News Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at